Phibro Animal Health completes acquisition of Zoetis’ medicated feed additive portfolio
The acquisition includes a portfolio with more than 37 product lines sold across about 80 countries
12 November 2024
2 minute read
By: Phibro Animal Health Corporation announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. This acquisition marks a significant step in furthering Phibro’s purpose to optimize global animal health and nutrition for better lives and a more sustainable world.
“Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro’s species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world,” said Jack C. Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation. “These products fit Phibro’s core competencies and capabilities while complementing our current lineup of vaccines, nutritional specialties and mineral nutrition.”
The acquisition includes a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of more than 300 employees who primarily support the manufacturing and distribution activities of the business. The agreement to acquire the business was announced on April 28, 2024.
The portfolio is expected to boost Phibro’s profitability and EBITDA margin and be accretive to its Adjusted Earnings Per Share. Additional financial details provided during Q1 earning call on November 7.
“This is a win-win-win,” noted Larry Miller, Phibro’s Chief Operating Officer. “For our customers, it broadens the solution options and expertise that Phibro brings to support animal health globally; for consumers, it helps continue to ensure that food is produced safely and sustainably; and for our investors, it expands and diversifies our revenue base, ultimately generating funding to support future investment in additional fast-growing animal health product categories.”
